VTVT (vTv Therapeutics) OCF Margin %: 24.85% (As of Mar. 2026)

What is vTv Therapeutics OCF Margin %?

vTv Therapeutics VTVT +3.27% 35 OCF Margin % is 24.85% as of Mar. 2026. GuruFocus rates VTVT with a GF Score™ of 35/100 and a GF Value™ of $7,827.31 (Significantly Undervalued). Among 960 Biotechnology companies, vTv Therapeutics ranks better than 56.77% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. vTv Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $9.15 Mil. vTv Therapeutics's Revenue for the three months ended in Mar. 2026 was $36.84 Mil. Therefore, vTv Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 24.85%.

As of today, vTv Therapeutics's current OCF Yield % is -7.16%.

The historical rank and industry rank for vTv Therapeutics's OCF Margin % or its related term are showing as below:

VTVT' s OCF Margin % Range Over the Past 10 Years
Min: -15312.71 Med: -813.37 Max: -215.99
Current: -28.27

During the past 13 years, the highest OCF Margin % of vTv Therapeutics was -215.99%. The lowest was -15312.71%. And the median was -813.37%.

VTVT's OCF Margin % is ranked better than
56.77% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs VTVT: -28.27

vTv Therapeutics OCF Margin % Related Terms

vTv Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics OCF Margin % Chart

vTv Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-482.10

-793.95

0.00

-2,488.40

0.00

vTv Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	24.85

VTVT vs CRDF, GUTS, ACOG: OCF Margin % Comparison

For the Biotechnology subindustry, vTv Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

vTv Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's OCF Margin % falls into.

Save Embed

35GF Score

vTv Therapeutics Inc VTVT

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

vTv Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

vTv Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-25.255	/	0
	=	%

vTv Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	9.154	/	36.839
	=	24.85 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of 24.85% mean?

vTv Therapeutics (VTVT) has a OCF Margin % of 24.85% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on vTv Therapeutics and its competitors. According to the industry distribution chart, vTv Therapeutics ranks #415 out of 960 companies in the Biotechnology industry, placing it in the top 43.2%.

Is vTv Therapeutics' OCF Margin % too high?

vTv Therapeutics' current OCF Margin % is 24.85%. Based on the distribution chart, vTv Therapeutics ranks #415 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, vTv Therapeutics has a GF Score™ of 35/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does vTv Therapeutics' OCF Margin % compare to CRDF and GUTS?

According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #415 out of 960 companies for OCF Margin %. This puts vTv Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current OCF Margin % is 24.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is vTv Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, vTv Therapeutics (VTVT) is currently considered Significantly Undervalued. The stock's GF Value™ is $7,827.31, compared to a current price of $36.91 — trading 99.5% below its estimated fair value. The current OCF Margin % is 24.85%. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For vTv Therapeutics (VTVT), the current OCF Margin % is 24.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (VTVT) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of $36.91 is trading 99.5% below its estimated GF Value™ of $7,827.31. GuruFocus considers vTv Therapeutics to be Significantly Undervalued.

Key valuation signals for VTVT:

OCF Margin %: 24.85%
GF Value™: $7,827.31 vs. price of $36.91 (99.5% below fair value)
GF Score™: 35/100

No single metric tells the full story. See the VTVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

vTv Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies CRDF GUTS ACOG BDTX ALPS GNLX ONCY KLRS ENGN NTHI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265

Website https://www.vtvtherapeutics.com

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

35GF Score

Get the complete analysis for VTVT

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.91

Price

$7,827.31

GF Value

View VTVT Analysis

See OCF Margin % data for all stocks →